| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England journal of medicine 368 (12), 1101-1110, 2013 | 434 | 2013 |
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial D Malka, P Cervera, S Foulon, T Trarbach, C de la Fouchardière, ... The lancet oncology 15 (8), 819-828, 2014 | 425 | 2014 |
| MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer NS Kamal, JC Soria, J Mendiboure, D Planchard, KA Olaussen, ... Clinical cancer research 16 (4), 1206-1215, 2010 | 118 | 2010 |
| Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database D Abadie, V Rousseau, S Logerot, J Cottin, JL Montastruc, F Montastruc Journal of clinical psychopharmacology 35 (4), 382-388, 2015 | 102 | 2015 |
| Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC … WE Pierceall, KA Olaussen, V Rousseau, E Brambilla, KM Sprott, F Andre, ... Annals of oncology 23 (9), 2245-2252, 2012 | 81 | 2012 |
| Adverse drug reactions to self‐medication: a study in a pharmacovigilance database A Berreni, F Montastruc, E Bondon‐Guitton, V Rousseau, D Abadie, ... Fundamental & clinical pharmacology 29 (5), 517-520, 2015 | 72 | 2015 |
| Pharmacovigilance of self-medication: a review of Adverse Drug Reactions (ADRs) registered in a pharmacovigilance database A Berreni, E Guitton, V Rousseau, D Abadie, F Montastruc, G Durrieu, ... FUNDAMENTAL & CLINICAL PHARMACOLOGY 29, 49-50, 2015 | 72* | 2015 |
| Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly … M Rouanne, C Massard, A Hollebecque, V Rousseau, A Varga, A Gazzah, ... European Journal of Cancer 49 (2), 431-438, 2013 | 54 | 2013 |
| Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer E Vacchelli, L Galluzzi, V Rousseau, A Rigoni, A Tesniere, N Delahaye, ... Oncoimmunology 1 (3), 271-278, 2012 | 49 | 2012 |
| Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: a descriptive study G Durrieu, J Jacquot, M Mège, E Bondon-Guitton, V Rousseau, ... Drug safety 39 (12), 1189-1195, 2016 | 47 | 2016 |
| Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting F Montastruc, H Bagheri, I Lacroix, C Damase-Michel, L Chebane, ... Drug safety 41 (5), 511-514, 2018 | 46 | 2018 |
| Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer X Ma, V Rousseau, H Sun, S Lantuejoul, M Filipits, R Pirker, H Popper, ... Molecular oncology 8 (3), 555-564, 2014 | 44 | 2014 |
| An original pharmacoepidemiological–pharmacodynamic method: application to antipsychotic‐induced movement disorders TTH Nguyen, A Pariente, JL Montastruc, M Lapeyre‐Mestre, V Rousseau, ... British journal of clinical pharmacology 83 (3), 612-622, 2017 | 41 | 2017 |
| Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database F Montastruc, C Duguet, V Rousseau, H Bagheri, JL Montastruc European journal of clinical pharmacology 70 (9), 1123-1127, 2014 | 40 | 2014 |
| Predictive Value of Susceptibility Vessel Sign for Arterial Recanalization and Clinical Improvement in Ischemic Stroke J Darcourt, P Withayasuk, I Vukasinovic, C Michelozzi, G Bellanger, ... Stroke 50 (2), 512-515, 2019 | 37 | 2019 |
| BINGO investigators: Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, noncomparative phase 2 trial D Malka, P Cervera, S Foulon, T Trarbach, C de la Fouchardière, ... Lancet Oncol 15 (8), 819-828, 2014 | 37 | 2014 |
| Can drugs induce or aggravate sleep apneas? A case–noncase study in VigiBase®, the WHO pharmacovigilance database M Linselle, A Sommet, E Bondon‐Guitton, F Moulis, G Durrieu, ... Fundamental & clinical pharmacology 31 (3), 359-366, 2017 | 35 | 2017 |
| Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years L Hauviller, F Eyvrard, V Garnault, V Rousseau, L Molinier, JL Montastruc, ... European journal of clinical pharmacology 72 (5), 631-639, 2016 | 30 | 2016 |
| Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial … D Malka, L Fartoux, V Rousseau, T Trarbach, E Boucher, ... Journal of Clinical Oncology 30 (15_suppl), 4032-4032, 2012 | 30 | 2012 |
| Underlying Small Vessel Disease associated with Mixed Cerebral Microbleeds C Blanc, A Viguier, L Calviere, M Planton, JF Albucher, V Rousseau, ... Frontiers in Neurology 10, 1126, 2019 | 29 | 2019 |
